A randomized phase II trial of concurrent temozolomide (TMZ) and radiotherapy (RT) followed by dose-dense compared to metronomic TMZ and maintenance cis-retinoic acid for patients with newly diagnosed glioblastoma multiforme (GBM)

被引：0
|
作者：
Clarke, Jennifer [1 ]
Sul, Joohee [1 ]
DeAngelis, Lisa [1 ]
Lassman, Andrew [1 ]
Hormigo, Adilia [1 ]
Nolan, Craig [1 ]
Gavrilovic, Igor [1 ]
Gu, Bin [1 ]
Panageas, Kathy [1 ]
Abrey, Lauren [1 ]
机构：
[1] Mem Sloan Kettering Canc Ctr, New York, NY 10021 USA
来源：
NEURO-ONCOLOGY | 2007年 / 9卷 / 04期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：530 / 530
页数：1
相关论文
共 50 条
  • [41] Randomized phase II trial of erlotinib (E) versus temozolomide (TMZ) or BCNU in recurrent glioblastoma multiforme (GBM): EORTC 26034
    Van den Bent, Martin
    Brandes, Alba
    Rampling, Roy
    Kouwenhoven, Mathilde
    Kros, Johan M.
    Carpentier, Antoine
    Clement, Paul
    Klughammer, Barbara
    Bakker, Brenda
    Lacombe, Denis
    Gorlia, Thierry
    NEURO-ONCOLOGY, 2007, 9 (04) : 522 - 522
  • [42] Health-related quality of life (HRQL) in VERTU: A randomized phase II trial of veliparib (V), radiotherapy (RT), and temozolomide (TMZ) for newly diagnosed MGMT unmethylated (uMGMT) glioblastoma (GBM).
    Sim, Hao-Wen
    Barnes, Elizabeth
    Lwin, Zarnie
    Rosenthal, Mark
    Wheeler, Helen
    Koh, Eng-Siew
    Foote, Matthew C.
    Fisher, Lauren
    Leonard, Robyn
    Hall, Merryn
    Simes, John
    Khasraw, Mustafa
    JOURNAL OF CLINICAL ONCOLOGY, 2019, 37 (15)
  • [43] Randomized phase II trial of erlotinib (E) versus temozolomide (TMZ) or BCNU in recurrent glioblastoma multiforme (GBM): EORTC 26034
    Van Den Bent, M. J.
    Brandes, A.
    Rampling, R.
    Kouwenhoven, M.
    Kros, J. M.
    Carpentier, A. F.
    Clement, P.
    Klughammer, B.
    Gorlia, T.
    Lacombe, D.
    JOURNAL OF CLINICAL ONCOLOGY, 2007, 25 (18)
  • [44] A phase I study of capecitabine and concurrent radiotherapy (RT) for patients with newly diagnosed glioblastoma multiforme (GBM).
    Newman, AJ
    Fiveash, J
    Rosenfeld, S
    Johnson, M
    Diasio, R
    Wang, W
    Cockrell-Donohue, AC
    Nabors, LB
    JOURNAL OF CLINICAL ONCOLOGY, 2004, 22 (14) : 116S - 116S
  • [45] Randomized phase II 8-arm factorial study of adjuvant dose-dense (dd) temozolomide (TMZ) with permutations of thalidomide (Thal), isotretinoin (CRA), and/or celecoxib (Cel) for newly diagnosed glioblastoma (GBM)
    Gilbert, Mark R.
    Hess, Kenneth R.
    Lagrone, Lore
    Groves, Morris D.
    Levin, Victor A.
    De Groot, John Frederick
    Loghin, Monica Elena
    Puduvalli, Vinay K.
    Fisch, Michael
    Giglio, Pierre
    Colman, Howard
    Conrad, Charles A.
    Aldape, Kenneth D.
    Yung, W. K. Alfred
    Anderson, M. D.
    JOURNAL OF CLINICAL ONCOLOGY, 2012, 30 (15)
  • [46] Phase II study of temozolomide (TMZ) administered on a 7 days on-7 days off regimen as primary treatment before radiotherapy (RT) in inoperable newly diagnosed glioblastoma multiforme (GBM)
    Chinot, D
    Barrié, M
    Cournède, A
    Dufour, H
    Figarella-Branger, D
    Braguer, D
    Peragut, JC
    Grisoli, F
    JOURNAL OF CLINICAL ONCOLOGY, 2005, 23 (16) : 119S - 119S
  • [47] SAFETY RESULTS FROM AVAglio, A PHASE III RANDOMIZED STUDY OF BEVACIZUMAB (BEV) PLUS STANDARD COMBINATION TEMOZOLOMIDE (TMZ) AND RADIOTHERAPY (RT) IN NEWLY DIAGNOSED GLIOBLASTOMA (GBM)
    Saran, Frank
    Chinot, Olivier L.
    Henriksson, Roger
    Mason, Warren
    Wick, Wolfgang
    Nishikawa, Ryo
    Dahr, Sunita
    Hilton, Magalie
    Garcia, Josep
    Cloughesy, Timothy
    NEURO-ONCOLOGY, 2013, 15 : 127 - 128
  • [48] Concurrent Temozolomide (TMZ) Improves Survival, but Increases Toxicity, in Elderly Patients with Glioblastoma Multiforme (GBM) Treated with Standard (STD) or Abbreviated (ABR) Radiotherapy (RT)
    Barker, C. A.
    Chang, M.
    Chou, J. F.
    Zhang, Z.
    Gutin, P. H.
    Beal, K.
    Abrey, L. E.
    Iwamoto, F. M.
    INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 2010, 78 (03): : S167 - S167
  • [49] Fatal hematologic toxicity with prolonged continuous administration of temozolomide (TMZ) during radiation therapy (RT) in the treatment of newly-diagnosed glioblastoma multiforme (GBM): Report of a Phase II trial.
    Doyle, TJ
    Mikkelsen, T
    Croteau, D
    Ali, H
    Anderson, J
    Beasse, R
    Rogers, L
    Rosenblum, M
    Ryu, S
    JOURNAL OF CLINICAL ONCOLOGY, 2005, 23 (16) : 125S - 125S
  • [50] Results of a Phase 2 Clinical Trial of Neo-Adjuvant Temozolomide (TMZ), Followed by Concurrent TMZ and Hypofractionated Accelerated External Beam Radiation Therapy (Ac-EBRT) With Limited Margins, and Adjuvant TMZ for Patients With Glioblastoma Multiforme (GBM)
    Shenouda, G.
    Souhami, L.
    Panet-Raymond, V.
    Abdulkarim, B.
    Cury, F.
    Owen, S.
    Kavan, P.
    Petrecca, K.
    Guiot, M.
    INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 2013, 87 (02): : S160 - S160
12345